Overall, there was a “modest” decline in use of embolic protection in the year after the PROTECTED TAVR results were released ...

Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...

DurAVR ® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 + 0.2 cm 2, a Mean Pressure Gradient (MPG) of 8.6 + 2.6 mmHg and Doppler ...

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Dr Rajneesh Kapoor highlights the evolution of structural heart disease treatments, exploring the impact of transcatheter ...

Aortic stenosis, a narrowing of the aortic valve, is one of the most common and severe structural issues, particularly in ...

WICHITA FALLS, Texas (KAUZ) - United Regional Health Care System is celebrating a major milestone in cardiovascular care as ...

Press Release Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and ...

2 Eligible patients had an aortic valve annulus area of ≤430 mm as measured by computed tomography, and suitable anatomy for transfemoral TAVR with both an Evolut PRO/PRO+/FX or a SAPIEN 3™/3 ...

The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...